NewTom VG3 digital radiography system from BIOLASE receives FDA clearance

BIOLASE announced NewTom VG3 digital panoramic, tomographic and cephalometric radiography unit received FDA clearance today, and will be marketed and distributed in the United States beginning in June for $50,000 to $120,000.

Offering a dynamic, single-rotation field of view, the VG3 is said to be an important contribution to the high-performance field of view offered by its predecessor, the VGi.  A modular hybrid 2D/3D system, the VG3 can start as a 2D system that is upgradable at any time to include a cephalometric sensor or 3D cone-beam-computed tomography with an 11” x 8” field of view.

Watch BIOLASE's Imaging Technology Manager Travis Harrison discuss why the NewTom VG3 is a unique entry into the market.

"We are very pleased that the NewTom BIOLASE VG3 has received FDA clearance in the U.S., said Federico Pignatelli, BIOLASE Chairman and Chief Executive Officer. “The VG3 fills a significant need for doctors who want to replace their older, film-based panoramic units with a competitively priced, modern digital 2D unit that offers flexibility to add 3D capabilities as they expand the range of endodontic and periodontic procedures they perform.”

Equipped with NewTom’s NNT 4.0 imaging analysis software, the VG3 includes patented Safebeam™ technology that releases the lowest possible dosage of radiation.  To eliminate the possibility of unnecessary exposures, Safebeam™ technology automatically adjusts radiation dosages and monitors systems operation, reportedly making it the safest system available for patients and staff.

BIOLASE specializes in the development and manufacturing of laser and other innovations that provide patients and dental practitioners with safer, more effective treatments.  Click here for a more comprehensive overview of the features and benefits of the NewTom VG3 digital x-ray system.